Who Needs Federal Drug Regulations? Scott Burris, JD Sarah - PowerPoint PPT Presentation

Mar 01, 2024 •267 likes •424 views

Mapping Medical Marijuana: Who Needs Federal Drug Regulations? Scott Burris, JD Sarah Krieger, MPH Leslie Allen, JD Rosalie Liccardo Pacula, PhD Jennifer K. Ibrahim, PhD, MPH Marijuanas Legal Status in the U.S. Medicine in a Legal Vacuum

Mapping Medical Marijuana: Who Needs Federal Drug Regulations? Scott Burris, JD Sarah Krieger, MPH Leslie Allen, JD Rosalie Liccardo Pacula, PhD Jennifer K. Ibrahim, PhD, MPH
Marijuana’s Legal Status in the U.S.
Medicine in a Legal Vacuum
States - “Laboratories of Democracy” • Beyond regulating legal drugs • Our study (1) provides a detailed mapping of current MM laws; and, (2) compares state vs. federal drug regulatory strategies
Data and Methods
Mapping Medical Marijuana (MM) As of July 2016, 24 states and the District of Columbia authorize the use of medical marijuana AK, AZ, CA, CO, CT, DC, DE, HI, IL, MA, MD, ME, MI, MN, MT, NH, NJ, NM, NV, NY, OR, PA, RI, VT, WA
Indications – er, Qualifying Diseases* # of states 0 5 10 15 20 25 30 PTSD Hepatitis C Amyotrophic Lateral Sclerosis Alzheimer's and/or Parkinson's Disease Crohn's disease Cachexia, cancer, glaucoma, HIV/AIDS, epilepsy, and/or multiple sclerosis *CA, DC, MA and NH authorize physicians to prescribe MM for any illness/symptom for which marijuana may provide relief
MM Product Safety Laws Label Requirements (21) Package Requirements (18) Mandatory Product Testing (14)
MM Dispensary Laws Product Supply Source (20) Waste Disposal (15) Dispensary Licensure (21)
Patient Protection Patient Registration & Patient Privacy (24) Patient Discrimination (12)
Regulating Medicine: Federal vs. State Regulation Federal State Drug indication Permits off-label use Qualifying condition required Drug safety/efficacy FDA - clinical trials & safety reporting N/A Patient privacy HIPAA Explicit privacy provisions Patient discrimination ADA prohibits discrimination Explicit discrimination provisions Restrict use locations N/A Prohibits MM use in specific places Treatment denial N/A State may revoke patient registration Dispensaries CSA - storage, purchase, sales reporting Regulates #, location, stock amount Product supply CSA - secure supply chain Regulates supply source Package/label FDA - label and package requirements Explicit MM package/label laws Medical waste CSA - disposal of unused medication Explicit waste protocols
Policy Experiment, Research Opportunity • Patient access and MM use • MM supply chain • Patient safety • Harm reduction ***How successful (or not) are states at regulating a new pharmaceutical product?***
Conclusion • “Medicine” without robust efficacy or safety testing • Unique regulatory challenge for states • Evolving legal landscape • Identify and promote effective policies
Questions? Temple’s Center for Public Health Law Research Team Scott Burris, JD Heidi Grunwald, PhD Lindsay Cloud, JD Jennifer Ibrahim, PhD Bethany Saxon, MS Prescription Drug Abuse Policy System (http://www.pdaps.org/)

Recommend

History of Federal History of Food and Drug Laws Regulations FDA has grown from a single chemist

Regulatory Issues in Laboratory Thursday, January 17th, 2008 Management History of Federal History of Food and Drug Laws Regulations FDA has grown from a single chemist in the US Food and Drug Department of Agriculture in 1862 to a staff of

521 views • 7 slides

DRUG FREE COMMUNITIES Federal Overview Coalitions & DFC Environmental Strategies

DRUG FREE COMMUNITIES Federal Overview Coalitions & DFC Environmental Strategies Performance to Date Future Directions 2 Cynthia Bentley Rubio, BSN, MHS USPHS Commander SAMHSA/CSAP/Division of Community Programs 1 Choke Cherry Rd, Rm

839 views • 44 slides

1 2 The federal food drug and cosmetic Act was originally passed in 1938 and required drugs be

1 2 The federal food drug and cosmetic Act was originally passed in 1938 and required drugs be proved safe. (click) In 1962, Congress amended the FD&C Act to add a requirement that, to obtain marketing approval, manufacturers demonstrate

580 views • 30 slides

Schedule II Drug Program Law Component . Analyzing State and Federal law and rules as they

1/29/2013 Schedule II Drug Program Law Component . Analyzing State and Federal law and rules as they apply to the authority to prescribe schedule II drugs. Mary Jane Maloney MSN APRN Past President , OAAPN Schedule II Law Component

339 views • 20 slides

The Federal Circuit month at Month at a Glance NO RELIEF FOR INNOVATOR DRUG LATE CLAIM TO

J U N E 2 0 0 2 Last The Federal Circuit month at Month at a Glance NO RELIEF FOR INNOVATOR DRUG LATE CLAIM TO INVENTION COSTS PARTY COMPANIES WHEN GENERIC IN INTERFERENCE COMPETITORS FAIL TO COMPLY WITH 35 U.S.C. 135(b) presents a

142 views • 12 slides

Evaluation of Drug-Drug Interactions and Their Influence on Drug Dosing in the Pediatric

Evaluation of Drug-Drug Interactions and Their Influence on Drug Dosing in the Pediatric Population Daniel Gonzalez, Pharm.D., Ph.D. Associate Professor Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy

578 views • 57 slides

Agenda Why Drug Importation? Legislative Framework for Drug Importation

11/13/2019 Drug Importation Stakeholder Update Senate Bill 19-005 Presented by: Kelly Swartzendruber , PharmD, Drug Importation, Health Care Policy & Finance 1 Agenda Why Drug Importation? Legislative Framework for Drug

522 views • 7 slides

IR IRRATIONAL DRUG USE Irrational drug use is a major problem. Can lead to drug-related

IR IRRATIONAL DRUG USE Irrational drug use is a major problem. Can lead to drug-related problems (DRP), which can cause patient morbidity and/ or mortality Ernst and Grizzles (2001) study: the cost of DRP for ambulatory patients

707 views • 14 slides

Drug-Testing Requirements for Companies An Overview of the SAMHSA 5 Commonly-Abused Drugs

Drug-Testing Requirements for Companies An Overview of the SAMHSA 5 Commonly-Abused Drugs Depending on the type of business, many companies fall under federal and state regulations that require employee drug testing. Certain industries,

357 views • 3 slides

Client Alert FDA Announces Proposed Changes to Clarify Orphan Drug Regulations Contact Attorneys

Client Alert FDA Announces Proposed Changes to Clarify Orphan Drug Regulations Contact Attorneys Regarding This Matter: The Food and Drug Administration (FDA) recently published a Federal Register Alan G. Minsk notice announcing proposed

285 views • 5 slides

Context Drug Related Deaths History of Drug Alert Systems in WM Changing Drug Use

Drug Alert Systems & Professional Information Systems 24 th January 2018 Tony Mercer Health Improvement Manager (Alcohol and other Drugs) Context Drug Related Deaths History of Drug Alert Systems in WM Changing Drug Use Trends

424 views • 11 slides

Schedule II Drug Pain Management Organizations 10 minutes Federal Rule 10 minutes Program

1/29/2013 Schedule II Law Component Schedule II Drug Pain Management Organizations 10 minutes Federal Rule 10 minutes Program Law Ohio Revised and Administrative Codes 30 minutes Pharmacy Board Medical Board Component

266 views • 10 slides

1 Drug littler that does appear everywhere, we need to remember that alcohol cans etc are a far

One obvious solution is drop boxes put in areas that have been identified as having a drug litter issue. This is no different to the current way we respond to none drug litter in an area with a problem you put a bin. 1 Drug littler that does

956 views • 31 slides

Importation of Unregistered Drug Products Center for Drug Regulation and Research Food and Drug

Republic of the Philippines Department of Health Food and Drug Administration Importation of Unregistered Drug Products Center for Drug Regulation and Research Food and Drug Administration Presentation Outline I. Food and Drug

741 views • 35 slides

Drug Effectiveness Review Project Alison Little, MD, MPH Drug Effectiveness Review Project

Drug Effectiveness Review Project Alison Little, MD, MPH Drug Effectiveness Review Project Medicaid Prescription Drug Quality and Cost Management: Options, Opportunities and Progress November 13, 2009 Beginnings 60% Increase in drug

459 views • 16 slides

Introduction to U.S. Drug Shortages CAPT Valerie Jensen, R.Ph. Associate Director Drug Shortage

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 Introduction to U.S. Drug Shortages CAPT Valerie Jensen, R.Ph. Associate Director Drug Shortage Program Center for Drug Evaluation & Research U.S. Food & Drug

464 views • 10 slides

Chemspace Drug Repurposing Description Drug discovery is a cost-consuming process. Different

Chemspace Drug Repurposing Description Drug discovery is a cost-consuming process. Different strategies exist to reduce the costs and maximize the outcome. Drug repurposing is one of the approaches, also referred to as drug repositioning or

603 views • 6 slides

Center for Drug Regulation and Research Food and Drug Administration Presentation Outline I.

685 views • 40 slides

Federal and State Cuts to 340B Drug Pricing Program Helen Jung 340B Cuts: Bottom Line $1.6

Federal and State Cuts to 340B Drug Pricing Program Helen Jung 340B Cuts: Bottom Line $1.6 billion will be cut from the program, effective January 1, 2018 Biggest Winners = For-Profit Hospitals Biggest Losers = Safety-Net Hospitals 340B

260 views • 12 slides

DRUG-FREE WORKPLACE PROGRAMS Working Drug Free Works! Presenters Amy Ronshausen Drug Free

DRUG-FREE WORKPLACE PROGRAMS Working Drug Free Works! Presenters Amy Ronshausen Drug Free America Foundation Karen Belanger Drug Free America Foundation Dr. Angel Prado Centros de Integracin Juvenil (CIJ) Ergin Beceren Turkish Green

733 views • 70 slides

Drug-Drug Interaction Extraction from Structured Drug Labels Dina Demner-Fushman 1 , Kin Wah Fung

Drug-Drug Interaction Extraction from Structured Drug Labels Dina Demner-Fushman 1 , Kin Wah Fung 1 , Phong Do 2 1 Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine 2 Office of Health Informatics, U.S.

263 views • 9 slides

Drug-Induced Liver Injury (DILI) Classification using US Food and Drug Administration

Drug-Induced Liver Injury (DILI) Classification using US Food and Drug Administration (FDA)-Approved Drug Labeling and FDA Adverse Event Reporting System (FAERS) data Qais Hatim, PhD Kendra Worthy, PharmD, MS Lilliam Rosario, PhD Why does

541 views • 43 slides

Damn it Jim, Im an EMT not a Doctor EMS Drug-Drug interactions and how not to be the

Damn it Jim, Im an EMT not a Doctor EMS Drug-Drug interactions and how not to be the grim reaper OBJECTIVES Examine EMS drugs and the interactions they have with other medications. Describe potential negative outcomes of

784 views • 47 slides

Chemspace Drug Impurities Description Drug impurities are undesirable compounds that accompany

Chemspace Drug Impurities Description Drug impurities are undesirable compounds that accompany the main drug. They are the result of side processes that are inevitable in large-scale organic synthesis. It is very important to collect data on

818 views • 6 slides